Cited 21 times in
A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2022-08-19T06:28:55Z | - |
dc.date.available | 2022-08-19T06:28:55Z | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189209 | - |
dc.description.abstract | Background This phase III study compared the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer (MRGC) who had experienced disease progression following first-line chemotherapy. Methods Patients were randomized to receive either paclitaxel (70 mg/m(2); days 1, 8, 15, every 4 weeks) or irinotecan (150 mg/m(2) every other week). The primary endpoint was progression-free survival (PFS). Results This study was stopped early due to low accrual rate. A total of 112 patients were enrolled; 54 were allocated to paclitaxel and 58 to irinotecan. Median PFS for the paclitaxel and irinotecan groups was 3.5 and 2.1 months, respectively (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.86-1.88; p = .234). Noninferiority of irinotecan to paclitaxel was not proved because the upper boundary of the 95% CI (1.88) exceeded the predefined upper margin of noninferiority (1.32). Median overall survival (OS) was 8.6 months in the paclitaxel group and 7.0 months in the irinotecan group (HR, 1.39; 95% CI, 0.91-2.11; p = .126). Among toxicities greater than or equal to grade 3, neutropenia (11.5%) was the most common, followed by peripheral neuropathy (7.7%) in the paclitaxel group, and neutropenia (34.5%) followed by nausea, vomiting, and anemia (8.6%, respectively) in the irinotecan group. Conclusion Although paclitaxel showed numerically longer PFS and OS compared with irinotecan, this was statistically insignificant. Both irinotecan and paclitaxel are valid second-line treatment options in MRGC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | AlphaMed Press | - |
dc.relation.isPartOf | ONCOLOGIST | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents, Phytogenic / pharmacology | - |
dc.subject.MESH | Antineoplastic Agents, Phytogenic / therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Irinotecan / pharmacology | - |
dc.subject.MESH | Irinotecan / therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Paclitaxel / pharmacology | - |
dc.subject.MESH | Paclitaxel / therapeutic use* | - |
dc.subject.MESH | Stomach Neoplasms / drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms / pathology | - |
dc.title | A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Chi Hoon Maeng | - |
dc.contributor.googleauthor | Tae-You Kim | - |
dc.contributor.googleauthor | Dae Young Zang | - |
dc.contributor.googleauthor | Yeul Hong Kim | - |
dc.contributor.googleauthor | In Gyu Hwang | - |
dc.contributor.googleauthor | Sang Cheul Oh | - |
dc.contributor.googleauthor | Joo Seop Chung | - |
dc.contributor.googleauthor | Hong Suk Song | - |
dc.contributor.googleauthor | Jin Won Kim | - |
dc.contributor.googleauthor | Su Jin Jeong | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.identifier.doi | 10.1634/theoncologist.2018-0142 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J02415 | - |
dc.identifier.eissn | 1549-490X | - |
dc.identifier.pmid | 30126861 | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | 조재용 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 18 | - |
dc.citation.endPage | e24 | - |
dc.identifier.bibliographicCitation | ONCOLOGIST, Vol.24(1) : 18-e24, 2019-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.